Ignite Creation Date:
2025-12-24 @ 10:04 PM
Ignite Modification Date:
2026-01-01 @ 7:47 AM
Study NCT ID:
NCT07071935
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-07-17
First Post:
2025-07-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Pilot Randomized Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)
Sponsor:
University of Pennsylvania
Organization:
Study Overview
Official Title:
A Pilot Randomized Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EVENT ALS
Brief Summary:
Amyotrophic lateral sclerosis (ALS) is a disease that causes weakness of the muscles of the body. The disease can eventually lead to severe breathing problems, which is the most common cause of death from ALS. The treatment for breathing is non-invasive ventilation (NIV). It is a machine that helps a person breathe by pushing air in and out of their lungs through a mask worn over the face. Research has shown that NIV can improve the quality of life and survival of someone with ALS. Unfortunately, NIV is not equally beneficial for everyone. We do not yet know the best time or method for starting NIV in ALS. Europe and Canada allow starting NIV much earlier in ALS than the United States. Current recommendations for starting NIV are based on the opinion of experts rather than large research studies. Medical insurance companies will not cover NIV until significant breathing weakness occurs. After NIV is started, we have no guidance on the best way to adjust NIV to benefit patients as much as possible. We know that some patients have difficulty tolerating NIV, but we do not know how to identify these individuals ahead of time.
Our research group has created a new prediction tool that can identify patients at high risk of breathing problems within the next 6 months. This may help us identify who is more likely to benefit from starting NIV early. We have published a paper that shows that NIV helps people with ALS live longer. This paper also showed that patients get more benefit if they use NIV for at least 4 hours per day. We published another paper that measured a gas called carbon dioxide (CO2), which goes high if someone's breathing is weakened. This paper showed that patients with ALS may live longer if they lower their CO2 levels using NIV. We also have data suggesting that certain characteristics may predict who is less likely to use NIV at least 4 hours per day.
In this study, we will collect pilot data on starting early NIV in individuals with ALS who do not yet meet insurance criteria for covering NIV. We will first use our prediction tool to identify patient risk. Then, subjects would be randomized to start early NIV or to usual care. The usual care group would eventually start NIV as they would if they were not in the study.
The purpose of this study is to collect data to help us plan a larger randomized clinical trial. Our study has 4 objectives. First, we want to identify individuals who would benefit from earlier NIV. We will use our original prediction tool to identify risk of severe breathing problems within the next 6 months. Second, we want to show that it is feasible to start NIV early. Third, we hope to gather data on the effect of randomization on symptoms, CO2 levels, and outcomes. Fourth, we want to identify traits that may make someone less likely to use NIV.
Our research group has created a new prediction tool that can identify patients at high risk of breathing problems within the next 6 months. This may help us identify who is more likely to benefit from starting NIV early. We have published a paper that shows that NIV helps people with ALS live longer. This paper also showed that patients get more benefit if they use NIV for at least 4 hours per day. We published another paper that measured a gas called carbon dioxide (CO2), which goes high if someone's breathing is weakened. This paper showed that patients with ALS may live longer if they lower their CO2 levels using NIV. We also have data suggesting that certain characteristics may predict who is less likely to use NIV at least 4 hours per day.
In this study, we will collect pilot data on starting early NIV in individuals with ALS who do not yet meet insurance criteria for covering NIV. We will first use our prediction tool to identify patient risk. Then, subjects would be randomized to start early NIV or to usual care. The usual care group would eventually start NIV as they would if they were not in the study.
The purpose of this study is to collect data to help us plan a larger randomized clinical trial. Our study has 4 objectives. First, we want to identify individuals who would benefit from earlier NIV. We will use our original prediction tool to identify risk of severe breathing problems within the next 6 months. Second, we want to show that it is feasible to start NIV early. Third, we hope to gather data on the effect of randomization on symptoms, CO2 levels, and outcomes. Fourth, we want to identify traits that may make someone less likely to use NIV.
Detailed Description:
Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with high morbidity and universal mortality predominantly due to respiratory failure. Non-invasive ventilation (NIV) improves quality of life (QoL) and extends survival in ALS beyond any medication.1-3 However, the best timing for NIV initiation is based only on expert opinion.4,5 For example, clinicians in the United States initiate NIV much later than European or Canadian guidelines,4,6,7 as payors do not cover NIV until significant respiratory impairment occurs. While potentially beneficial, early NIV initiation could increase burden for patients due to mask intolerance, claustrophobia, and disturbed sleep, possibly negating any clinical benefit. Similarly, there are no surrogate endpoints to guide NIV settings and mask selection. Thus, clinicians employ generic approaches despite significant disease heterogeneity. Given the variable onset and progression of ALS, strategies for anticipating respiratory risk and personalizing NIV management are critical to maximize NIV benefit while reducing its burden.
Our ultimate goal is to conduct Phase III multicenter clinical trials which investigate early NIV strategies to improve quality of life and survival in individuals with ALS. Before embarking on a large RCT of early NIV in ALS, we first must collect pilot data on feasibility, effect sizes, and personal factors associated with NIV usage. Our prior work has developed a novel clinical prediction tool which can stratify ALS patients at presentation into high versus low risk of respiratory insufficiency within 6 months, capable of identifying an enriched subgroup suitable for an interventional study. We have performed semi-structured interviews which suggest that ALS patients value being proactive about their respiratory care. We have shown that improving transcutaneous carbon dioxide (CO2) levels is associated with improved survival in ALS, suggesting that transcutaneous CO2 could be a surrogate endpoint for guiding NIV management. We also have found that factors at time of NIV initiation, such as ALSFRS-R speech and dyspnea scores, are significantly associated with NIV adherence.
Clinical Intervention: In this RCT of patients who have yet to meet insurance criteria for NIV coverage, we will randomize individuals to early NIV versus usual care, stratified by 6-month risk of respiratory insufficiency as determined by our novel clinical prediction tool.
Objective(s): Our objectives in this pilot study are to collect: 1) feasibility data on randomization to early NIV; 2) estimates of effect sizes of early NIV versus usual care on endpoints such as QoL, transcutaneous CO2, symptoms, and survival; and 3) identify factors present at time of NIV initiation which predispose to low hourly usage of NIV. We will analyze our results across randomization groups, as well as assess the interaction between randomization and predicted risk of respiratory insufficiency.
Study Design: We will conduct a 3-center phase II pilot randomized clinical trial of incident ALS patients diagnosed in the last 6 months.
Clinical Impact: The proposed study will help us understand the feasibility and safety of starting early NIV in ALS. We will assess effect sizes on clinical endpoints, which will be critical for planning a future large RCT. Lastly, we will learn about patient characteristics that may predispose to lower NIV adherence. We will examine our results across randomization and the interaction with predicted risk of respiratory insufficiency. Leveraging our clinical prediction tool may help identify an enriched patient population suitable for future interventional studies.
Our ultimate goal is to conduct Phase III multicenter clinical trials which investigate early NIV strategies to improve quality of life and survival in individuals with ALS. Before embarking on a large RCT of early NIV in ALS, we first must collect pilot data on feasibility, effect sizes, and personal factors associated with NIV usage. Our prior work has developed a novel clinical prediction tool which can stratify ALS patients at presentation into high versus low risk of respiratory insufficiency within 6 months, capable of identifying an enriched subgroup suitable for an interventional study. We have performed semi-structured interviews which suggest that ALS patients value being proactive about their respiratory care. We have shown that improving transcutaneous carbon dioxide (CO2) levels is associated with improved survival in ALS, suggesting that transcutaneous CO2 could be a surrogate endpoint for guiding NIV management. We also have found that factors at time of NIV initiation, such as ALSFRS-R speech and dyspnea scores, are significantly associated with NIV adherence.
Clinical Intervention: In this RCT of patients who have yet to meet insurance criteria for NIV coverage, we will randomize individuals to early NIV versus usual care, stratified by 6-month risk of respiratory insufficiency as determined by our novel clinical prediction tool.
Objective(s): Our objectives in this pilot study are to collect: 1) feasibility data on randomization to early NIV; 2) estimates of effect sizes of early NIV versus usual care on endpoints such as QoL, transcutaneous CO2, symptoms, and survival; and 3) identify factors present at time of NIV initiation which predispose to low hourly usage of NIV. We will analyze our results across randomization groups, as well as assess the interaction between randomization and predicted risk of respiratory insufficiency.
Study Design: We will conduct a 3-center phase II pilot randomized clinical trial of incident ALS patients diagnosed in the last 6 months.
Clinical Impact: The proposed study will help us understand the feasibility and safety of starting early NIV in ALS. We will assess effect sizes on clinical endpoints, which will be critical for planning a future large RCT. Lastly, we will learn about patient characteristics that may predispose to lower NIV adherence. We will examine our results across randomization and the interaction with predicted risk of respiratory insufficiency. Leveraging our clinical prediction tool may help identify an enriched patient population suitable for future interventional studies.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| HT9425-25-1-0154 | OTHER_GRANT | Department of Defense | View |